Mobia Medical, Inc. (MOBI)
| Market Cap | 455.59M |
| Revenue (ttm) | 32.04M +104.8% |
| Net Income | -46.50M |
| EPS | -20.64 |
| Shares Out | 33.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 291,461 |
| Open | 14.08 |
| Previous Close | 13.78 |
| Day's Range | 13.25 - 14.16 |
| 52-Week Range | 10.19 - 14.77 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 16.67 (+21.06%) |
| Earnings Date | Jun 16, 2026 |
About MOBI
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MOBI stock is "Buy." The 12-month stock price target is $16.67, which is an increase of 21.06% from the latest price.
News
Mobia Medical initiated with a Buy at BofA with ‘long growth runway’
As previously reported, BofA initiated coverage of Mobia Medical (MOBI) with a Buy rating and $16 price target Mobia has a first mover advantage with its vagus nerve stimulator Vivistim…
Mobia Medical initiated with a Buy at BTIG
BTIG initiated coverage of Mobia Medical (MOBI) with a Buy rating and $19 price target The company develops and commercializes Vivistim, the first and only FDA-approved vagus nerve stimulator platform...
Mobia Medical initiated with a Buy at BofA
BofA initiated coverage of Mobia Medical (MOBI) with a Buy rating and $16 price target
Mobia Medical initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Mobia Medical (MOBI) with an Overweight rating and $15 price target Mobia is commercializing Vivistim Paired Vagus Nerve Stimulation, the first and only FDA-approved the...
Mobia Medical initiated with a Buy at Goldman Sachs
Goldman Sachs analyst David Roman initiated coverage of Mobia Medical (MOBI) with a Buy rating and $31 price target The company offers exposure to a “large and untapped” addressable market…
Mobia Medical indicated to open at $19.50, IPO priced at $15
Mobia Medical (MOBI) priced 10M shares at $15.00. The deal priced at the midpoint of the $14.00-$16.00 range. BofA, JPMorgan, Goldman Sachs, BTIG and Wolfe Research are acting as joint…
Mobia Medical indicated to open at $15, IPO priced at $15
11:44 EDT Mobia Medical (MOBI) indicated to open at $15, IPO priced at $15
Mobia Medical opens at $14, IPO priced at $15 per share
Mobia Medical (MOBI) priced 10M shares at $15.00. The deal priced at the midpoint of the $14.00-$16.00 range. Mobia is a commercial-stage medical device company that says it is “redefining…
Mobia Medical 10M share IPO priced at $15.00
The deal priced at midpoint of $14.00-$16.00. BofA, JPMorgan, Goldman Sachs, BTIG and Wolfe Research are acting as joint book running managers for the offering.
Mobia Medical Announces Pricing of Initial Public Offering
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI) (“Mobia Medical”), a commercial-stage medical device company redefining stroke recovery for survivors living with lif...
Mobia Medical IPO Registration Document (S-1)
Mobia Medical has filed to go public with an IPO on a public market